EUVIMEDEUVIMED entdecken
Open Access

Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists

Rasha Alhiary, Aaron S Kesselheim, Sarah Gabriele, Reed F Beall, S Sean Tu, William B Feldman

JAMA · 15.08.2023 · 330 (7) · 650

DOI: 10.1001/jama.2023.13872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 15.08.2023. Verfasst von Rasha Alhiary und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Drug Approval, Drugs, Generic, Hypoglycemic Agents. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive.

Objective

To analyze how manufacturers of brand-name GLP-1 receptor agonists have used the patent and regulatory systems to extend periods of market exclusivity. Evidence Review The annual US Food and Drug Administration’s (FDA) Approved Drug Products With Therapeutic Equivalence Evaluations was used to identify GLP-1 receptor agonists approved from 2005 to 2021 and to record patents and nonpatent statutory exclusivities listed for each product. Google Patents was used to extract additional data on patents, including whether each was obtained on the delivery device or another aspect of the product. The primary outcome was the duration of expected protection from generic competition, defined as the time elapsed from FDA approval until expiration of the last-to-expire patent or regulatory exclusivity.

Findings

On the 10 GLP-1 receptor agonists included in the cohort, drug manufacturers listed with the FDA a median of 19.5 patents (IQR, 9.0-25.8) per product, including a median of 17 patents (IQR, 8.3-22.8) filed before FDA approval and 1.5 (IQR, 0-2.8) filed after FDA approval. Fifty-four percent of all patents listed on GLP-1 receptor agonists were on the delivery devices rather than active ingredients. Manufacturers augmented patent protection with a median of 2 regulatory exclusivities (IQR, 0-3) obtained at approval and 1 (IQR, 0.3-4.3) added after approval. The median total duration of expected protection after FDA approval, when accounting for both preapproval and postapproval patents and regulatory exclusivities, was 18.3 years (IQR, 16.0-19.4). No generic firm has successfully challenged patents on GLP-1 receptor agonists to gain FDA approval. Conclusions and Relevance Patent and regulatory reform is needed to ensure timely generic entry of GLP-1 receptor agonists to the market.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Drug ApprovalDrugs, GenericHypoglycemic AgentsPatents as TopicGlucagon-Like Peptide-1 Receptor AgonistsHumansPharmaceutical PreparationsUnited StatesTherapeutic EquivalencyCommerceEconomic CompetitionTime Factors

Substanzen

Drugs, GenericPharmaceutical PreparationsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • West Virginia University College of Law, Morgantown.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Alhiary, R., Kesselheim, A. S., Gabriele, S., Beall, R. F., Tu, S. S., & Feldman, W. B. (2023). Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA, 330(7), 650. https://doi.org/10.1001/jama.2023.13872

Vancouver

Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA. 2023;330(7):650. doi:10.1001/jama.2023.13872

BibTeX
@article{Alhiary2023,
  author = {Alhiary, Rasha and Kesselheim, Aaron S and Gabriele, Sarah and Beall, Reed F and Tu, S Sean and Feldman, William B},
  title = {Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {7},
  pages = {650},
  doi = {10.1001/jama.2023.13872}
}
Kostenlos starten →